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The evolution of human diets led to preferences towards polyunsaturated fatty acid 
(PUFA) content with ‘Western’ diets enriched in ω-6 PUFAs. Mounting evidence points 
to ω-6 PUFA excess limiting metabolic and cognitive processes that define longevity in 
humans. When chosen during pregnancy, ω-6 PUFA-enriched ‘Western’ diets can 
reprogram maternal bodily metabolism with maternal nutrient supply precipitating the 
body-wide imprinting of molecular and cellular adaptations at the level of long-range 
intercellular signaling networks in the unborn fetus. Even though unfavorable 
neurological outcomes are amongst the most common complications of intrauterine ω-
6 PUFA excess, cellular underpinnings of life-long modifications to brain architecture 
remain unknown. Here, we show that nutritional ω-6 PUFA-derived endocannabinoids 
desensitize CB1 cannabinoid receptors, thus inducing epigenetic repression of 
transcriptional regulatory networks controlling neuronal differentiation. We found that 
cortical neurons lose their positional identity and axonal selectivity when mouse 
fetuses are exposed to excess ω-6 PUFAs in utero. Conversion of ω-6 PUFAs into 
endocannabinoids disrupted the temporal precision of signaling at neuronal CB1 
cannabinoid receptors, chiefly deregulating Stat3-dependent transcriptional cascades 
otherwise required to execute neuronal differentiation programs. Global proteomics 
identified the immunoglobulin family of cell adhesion molecules (IgCAMs) as direct 
substrates, with DNA methylation and chromatin accessibility profiling uncovering 
epigenetic reprogramming at >1,400 sites in neurons after prolonged cannabinoid 
exposure. We found anxiety and depression-like behavioral traits to manifest in adult 
offspring, which is consistent with genetic models of reduced IgCAM expression, to 
suggest causality for cortical wiring defects. Overall, our data uncover a regulatory 
mechanism whose disruption by maternal food choices could limit an offspring’s brain 




Establishing the cerebral connectome relies on mechanisms that produce unique topological 
specificity for each neuron to receive up to 30-40,000 synapses (1) for information exchange. 
Pyramidal cells and GABA interneurons, modulated by subcortical afferents, construct 
cortical microcircuits that represent the cellular backbones of high-order integrative 
processes. During the fetal period, telencephalic stem cell pools contribute neurons to the 
cerebral cortex (2, 3): neuroblasts engage in long-distance migration along complex 
trajectories for layer-specific homing before their terminal morphogenesis, including the 
specification and directional growth of their axons, can commence (2). These developmental 
stages are controlled by intercellular signals (including activity-dependence, morphogens and 
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chemotaxic cues) that engage transcriptional differentiation programs intracellularly to define 
neuronal identity (3). 
 
Fetal development relies on sequential cell divisions that generate tissue mass and topological 
specificity for which nutrients are transferred along maternal-placental-fetal nutrient 
interfaces (2). A critical metabolic demand for both cell division and morphological 
differentiation is the availability of membrane lipid precursors to envelop developing cells. 
Accordingly, about half of the dry weight of the brain is made up by lipids, of which 20-25% 
are long-chain polyunsaturated fatty acids (PUFAs) (4), with 20:4 ω-6 arachidonic acid (AA) 
being a prominent constituent. Incorporation of long-chain PUFAs into biological membranes 
allows for well-controlled membrane expansion as axons and dendrites form (5). They also 
play important roles in trans-membrane transport and receptor-dependent second messenger 
signaling (4). Significantly, AA also serves as the ultimate precursor to eicosanoids, 
including their non-classical endocannabinoid subfamily (6): i) sn-2-AA containing 
diacylglycerols, which are cleaved by sn-1-diacylglycerol lipases to generate 2-
arachydonoylglycerol (2-AG; sn designation for stereospecific numbering by convention; 
(7)), or ii) N-arachidonoyl-phosphatidylethanolamine (NAPE), which is cleaved by a NAPE-
selective phospholipase D to generate N-arachidonoylethanolamine (anandamide, AEA; (6, 
8)). Significantly, 2-AG in the developing brain engages CB1 cannabinoid receptors (CB1Rs) 
on neurons to act as repulsive guidance cue for cell migration (9) and to inhibit neurite 
outgrowth and morphogenesis (9, 10) (Fig. S1a,b). Despite these inferences, causality 
between maternal PUFA metabolism and the (de-)regulation of local-acting instructive lipid 
signals indispensable for cortical development (4) and influencing neurodevelopmental 
outcomes has not been established. 
 
The bulk of fetal PUFAs (including AA) available for signaling and in lipid depots are of 
maternal origin, despite fetal lipogenesis becoming progressively operational from mid-
gestation (11). Accordingly, maternal dietary choices commonly impact birth weight, 
neurological status, postnatal cognition and life expectancy in both humans and rodent 
models (11). Medical guidelines highlight maternal food intake during pregnancy as a major 
factor for child development with a near-equivalent ratio of ω-3 (rich in fish and ‘Japanese’ 
diet) and ω-6 PUFAs recommended as dietary optimum (12) to satisfy basic metabolic 
demands by sustained precursor availability and to prevent adverse neurological outcomes 
(13). However, with more than 30% of children born to overweight/obese mothers (14); a 
dramatic deviation from this dietary optimum likely exists for prolonged periods, as either the 
relative or the total amount of ω-6 PUFAs being in excess (15). Therefore, ‘Western’ diets 
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rich in ω-6 PUFA precursors are likely to be detrimental for intrauterine development (14). 
The consumption of ω-6 PUFA-rich diets prior to conception is equally alarming since the 
composition of pre-existing maternal fat depots that undergo accelerated breakdown during 
the last trimester of pregnancy (14) determine the molecular diversity of bioactive lipid 
precursors for the fetus as it develops. Moreover, in both humans and rodents (16, 17) high-
fat diets increase AA in the circulation that in turn increases the availability of 
endocannabinoids and, consequently, modulates the function of the endocannabinoid system 
(15). Yet a mechanistic and causal relationship between a shift towards maternal ω-6 PUFA 
preference (even if retaining a relative ω-3:ω-6 PUFA ratio) and life-long 
neurodevelopmental deficits that render the offspring’s nervous system prone to postnatal 
maladaptation remains unknown. 
 
 
Materials & Methods 
Animals, feeding regime and tissue collection. Female C57Bl6/J, cholecystokinin 
(CCK)BAC/DsRed and CCKBAC/DsRed::GAD67gfp/+ transgenic mice (18) were housed in groups in 
clear plastic cages on a 12h/12h light/dark cycle (lights on at 08:00 h) and in a temperature 
(22 ± 2 °C) and humidity (50 ± 10%)-controlled environment. Food and water were available 
ad libitum. Embryos and tissues were obtained from timed matings with the day of vaginal 
plug considered as embryonic day (E) 0.5. The day of birth was always registered as 
postnatal day (P) 0. Groups sizes conformed to those used as convention in developmental 
biology (10, 19-21). 
 
Female animals at 6 weeks of age were randomly assigned to either a hypercaloric diet 
enriched ~15-fold in ω-6 PUFAs while maintaining the ω-3:ω-6 PUFA ratio at 1:8 as in 
standard chow or to a standard diet (Fig. S2a-b1 and Table S1). Diets were from Special Diet 
Services (United Kingdom) and quality controlled by mass-spectrometry. Maternal body 
weight was recorded 2-3 times per week for the duration of each study (Fig. S2c). The effect 
of maternal diets on fetal brain development was evaluated at E18.5 after both the ‘priming 
protocol’ (consuming a high ω-6 PUFA diet starting 2 weeks prior to conception; Fig. S2b) 
or ‘programming protocol’ (consuming a high ω-6 PUFA diet 8 weeks prior to conception, 
Fig. S2b1). This experimental approach, which precluded blinding the investigators, was 
motivated by i) the switch of diets inducing transient changes in appetite and even loss of 
body weight, which, if occurring acutely could have biased fetal development and ii) changes 
in copulatory behaviors affecting both males and females on the first days of being exposed 
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to the modified diet. Moreover, long-lasting postnatal effects of maternal ω-6 PUFA-enriched 
diets were determined in adult offspring on P75. 
 
Embryos were collected from n ≥ 5 pregnancies to keep the number of independent 
observations sufficient for statistical analyses, sexed if appropriate, and used for 
histochemistry, proteomics, lipid analysis and molecular biology. The use of specific or 
mixed genders for particular experiments was specified. Embryos were collected by Cesarean 
sections from mothers anesthetized by isoflurane (5%, 1 L/min flow rate), weighed and 
decapitated with their heads either immersed in 4% paraformaldehyde (PFA) in 0.1 M Na+ 
phosphate buffer (PB; pH 7.4) overnight or snap-frozen in liquid N2 and stored at -80 °C until 
further processing (10, 18). Likewise, adult offspring were anesthetized in isoflurane (5%, 1 
L/min flow rate), decapitated, with their brain tissues snap-frozen in liquid N2 and stored at -
80 °C. 
 
Ethical approval of animal studies. Experiments on live animals conformed to the 
2010/63/EU European Communities Council Directive and were approved by the Austrian 
Ministry of Science and Research (66.009/0145-WF/II/3b/2014, and 66.009/0277-
WF/V/3b/2017). Particular effort was directed towards minimizing the number of animals 
used and their suffering during experiments. 
 
Click-iT EdU labelling. Embryos were exposed to a single maternal intraperitoneal injection 
of 5-ethynyl-2’-deoxyuridine (EdU, 33 mg/kg) at E14.5 (in the ‘programming protocol’ 
only). At E18.5, male embryos were selected by PCR genotyping (see Ref. (19) for primer 
pairs and protocol). Embryonic brains were immersion fixed in 4% PFA in PB overnight, 
rinsed in PB and cryoprotected in 30% sucrose (in PB) for 48 h. Serial coronal sections (20 
 μm) were cut on a ThermoFisher NX70 cryostat, thaw-mounted onto fluorescence-free 
SuperFrost+ glass slides and stored at -20°C until processing. EdU was visualized with Alexa 
488-azide using the Click-iT labeling technology (Life Technologies) (22). 
 
Immunohistochemistry and quantitative morphometry. Immunofluorescence 
histochemistry was performed according to published protocols (10, 18, 19). Briefly, sections 
were extensively rinsed in PB and subsequently exposed to a blocking solution consisting of 
5% normal donkey serum (NDS; Jackson ImmunoResearch), 1% bovine serum albumin 
(BSA; Sigma), and 0.3% Triton X-100 (Sigma) in PB for 2 h at 21-24°C. Next, sections were 
incubated with either anti-neural cell adhesion molecule L1 (L1CAM; 1:1,000, #ABT143, 
Millipore), or anti-Ki67 (which marks proliferation/early neuroblasts; 1:100, #AB9260, 
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Millipore) primary antibody diluted in PB also containing 0.1% NDS and 0.3% Triton X-100 
at 4°C for 48 h. Limbic system associated membrane protein (LSAMP) was localized to 
cortical territories of male CCKBAC/DsRed transgenic mice at E18.5 by first exposing glass-
mounted coronal sections to a 0.1 M Tris-glycine solution (pH 7.4; Sigma) at 21-24 oC for 20 
min. After rinsing in 0.05 M phosphate-buffered saline (PBS), sections were incubated with 
mouse anti-LSAMP primary antibody (1:50; #2G9, Developmental Studies Hybridoma Bank) 
for 48h (Dr. Pimenta Aurea’s suggestions for histochemistry are greatly acknowledged). 
DyLight Fluor 488-tagged secondary antibodies (1:300; Jackson ImmunoResearch) were 
used to reveal the localization of primary antibodies. Sections were coverslipped with 
Aquamount (Dako). Images were acquired on Zeiss 700LSM and 880LSM confocal laser 
scanning microscopes. Multi-panel images were assembled in CorelDRAW X7 (Corel 
Corp.). 
 
Axonal morphometry was performed as described earlier (10, 19). In brief, the diameter of 
first-order bundles made up by corticofugal axons on E18.5 was measured in serial sections 
of 20 μm thickness that had been cut and processed as above. The number of immunoreactive 
or genetically-tagged neurons in the fetal cerebral cortex was determined using equivalent 
and binned surface areas, and expressed as absolute values.  
 
Liquid chromatography-atmospheric pressure chemical ionization mass spectrometry. 
Extraction, purification, and quantification of 2-AG and AEA from cortical tissues of E18.5 
embryos and P75 mice (for embryos also including dorsal hippocampus) fed with either 
hypercaloric or standard diet were carried out according to published protocols (23, 24). 
Briefly, tissues were rapidly dissected out, snap-frozen in liquid N2 and stored at -80 °C. 
After lipid extraction and prepurification on silica gel columns, 2-AG and AEA levels from n 
= 3 animals/condition were determined by isotope dilution using liquid chromatography-
atmospheric pressure chemical ionization mass spectrometry (Shimadzu LCMS-2020). 
Results were expressed as pmol/mg of tissue. 
 
iTRAQ proteomics. Single cortical hemispheres (n = 6/group, mixed and balanced for sex 
from independent pregnancies) were obtained from E18.5 fetuses. Contralateral hemispheres 
were snap frozen for target validation by quantitative real-time PCR and/or Western blotting 
(see below). Proteins were extracted by homogenization in lysis buffer (pH 10.0) of 
triethylammonium bicarbonate (25 mM, Sigma), Na2CO3 (20 mM, Sigma) in the presence of 
protease inhibitors (cocktail; Sigma). Protein concentrations were determined by the 
bicinchoninic acid assay (BCA; ThermoFisher). After quantification, proteins were 
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precipitated in 6 volumes of ice-cold acetone. One hundred µg of proteins per sample were 
used for isobaric tagging for relative and absolute quantitation (iTRAQ) in an 8-plex layout 
per the manufacturer’s instructions (ABSciex). In brief, proteins were denatured, reduced, 
alkylated, trypsin digested (Promega), individually labeled with appropriate iTRAQ tags, 
pooled, concentrated, re-suspended in 1.4 ml loading buffer (10 mM KH2PO4 pH 3.0 in 25% 
acetonitrile) and sonicated. 
 
Peptides were separated by cation exchange chromatography on a PolySulfoethyl A column 
(PolyLC) over 30 min with a KCl gradient increasing up to 0.5 M, and 0.5 ml fractions 
collected. Fifteen fractions across the elution profile of similar peptide concentration were 
generated and concentrated (SpeedVac). Fractions were re-suspended in 0.1% trifluoroacetic 
acid (TFA) and desalted on C18 spin columns (PepClean C18, Thermo Scientific). Half of 
each fraction was then injected on an Acclaim PepMap 100 C18 trap and an Acclaim PepMap 
RSLC C18 column (ThermoFisher), using a nanoLC Ultra 2D plus loading pump and 
nanoLC as-2 autosampler (Eksigent). The peptides were loaded onto the trap in a mixture of 
98% water, 2% acetonitrile and 0.05% TFA, and washed for 20 min to waste before 
switching in line with the column and were then eluted with a gradient of increasing 
acetonitrile, containing 0.1 % formic acid (2-20% acetonitrile in 90 min, 20-40% in a further 
30 min, followed by 98% acetonitrile to clean the column, before re-equilibration to 2% 
acetonitrile). The eluate was sprayed into a TripleTOF 5600 electrospray tandem mass 
spectrometer (ABSciex) and analyzed in Information Dependent Acquisition (IDA) mode, 
performing 120 ms of MS followed by 80 ms MSMS analyses on the 20 most intense peaks 
seen by MS, with the „Adjust Collision Energy when using iTRAQ reagent“ box ticked in the 
method. 
 
Data files were processed by ProteinPilot 4.5 (Sciex) using the Paragon algorithm, searching 
against the SwissProt database (March 2013 edition). The following settings were selected: 
sample type: iTRAQ 8-plex (peptide labelled), cysteine alkylation: MMTS, digestion: trypsin, 
instrument: TripleTOF 5600, species: mouse, ID focus: biological modifications and amino 
acid substitutions and search effort: thorough. Results files were exported to Microsoft Excel 
(Table S2), with statistical analysis in SPSS v. 21. 
 
RNA isolation and quantitative PCR. RNA was extracted using the RNeasy mini kit 
(Qiagen) with a DNase I step performed to eliminate traces of genomic DNA. Total RNA 
was then reverse transcribed to a cDNA library in a reaction mixture using a high-capacity 
cDNA reverse transcription kit (Applied Biosystems). The cDNA library was then used for 
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quantitative real-time PCR (CFX-connect, Bio-Rad). Pairs of PCR primers specific for neural 
cell adhesion molecule L1 (L1cam), neural cell adhesion molecule 1 (Ncam), limbic system-
associated membrane protein (Lsamp), neurotrimin (Ntm), cannabinoid receptor 1 (Cnr1), 
signal transducer and activator of transcription 3 (Stat3), myeloblastosis oncogene (Myb) and 
the CCAAT/enhancer-binding protein beta (Cebpb) were designed with Primer Bank and 
National Center for Biotechnology Information (NCBI) Primer Blast software (Table S3). 
Quantitative analysis of gene expression was performed with the SYBR Green Master Mix 
Kit (Life Technologies). Expression levels were normalized to the housekeeping gene 
encoding glyceraldehyde-3-phosphate dehydrogenase (Gapdh) for every sample in parallel 
assays. 
 
Quantitative Western blotting with total protein normalization. Cerebral samples of 
E18.5 male embryos and postnatal mice (mixed for sex) were obtained as described above. 
Total protein labeling was initiated by adding carbocyanine (Cy)5 dye reagent (GE 
Healthcare) that had been pre-diluted (1:10) in ultrapure water. Samples were mixed and 
incubated for 5 min at 21-24 oC. The labeling reaction was terminated by adding Amersham 
WB loading buffer (GE Healthcare; 20 μl/sample) containing 40 μM DTT. Samples were 
then boiled at 95 °C for 3 min with equal amounts (20 μg/40 μl) and subsequently loaded 
onto an Amersham WB gel card (13.5%). Electrophoresis (600V, 42 min) and protein 
transfer onto polyvinylidine-difluoride membranes (100V, 30 min) were at default settings in 
an integrated Amersham WB system (GE Healthcare) for quantitative SDS-PAGE and 
Western blotting of proteins with fluorescence detection. After blocking, membranes were 
incubated with guinea pig anti-CB1R antibody (1:500, kindly provided by Dr. Masahiko 
Watanabe) and mouse anti-LSAMP antibody (1:100; #2G9, Developmental Studies 
Hybridoma Bank) overnight. To demonstrate the specificity of the guinea pig anti-CB1R 
antibody, we prepared cerebellar homogenates from wild-type and Cnr1-/- littermates. A 
specific band at the calculated molecular weight of this receptor (53 kDa) was detected in 
wild-type mice but not Cnr1-/- mice (see Results below). Antibody binding was detected by 
using species-specific (anti-mouse and anti-guinea pig) Cy3-labeled secondary antibodies 
(1:1,000; GE Healthcare). Membranes were dried before scanning at 560 nm (Cy3) and 630 
nm (Cy5) excitation. Automated image analysis was performed with the Amersham WB 
evaluation software with manual optimization if necessary. 
 
Behavioral tests. Anxiety-like behavior in the first generation offspring to dams fed with ω-6 
PUFA-enriched or control chow were tested in the open-field and elevated plus maze (n = 6 
male mice/group from independent pregnancies) as described (25, 26, 27). In the open-field 
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test, mice were allowed to explore a 50 × 50 cm arena for 5 minutes. The total distance 
travelled (m), their speed of movement (cm/s) and the time spent in an inner 15 cm-area (s) 
were measured. For the elevated plus maze, mice were placed in the center of a standard 
maze with its perpendicular arms measuring 10 × 50 cm each. Mice faced an open arm at 
start, and were allowed to explore the maze for 5 min. The distance travelled (cm) and the 
time spent (s) in the open and closed arms were measured and the number of arm entries (n) 
were determined. Parameters for the open arms (distance, time, entries) were expressed as the 
percentage of total arm entries. 
 
Cultures of cortical neurons and IncuCyte-assisted neurite tracking. Cerebral tissues 
(cortex/hippocampus) of mouse embryos were isolated at E14.5 (mixed for sex) or E18.5 
(males only). Cells were mechanically dissociated into single cell suspension by trypsin 
digestion (0.1%, 3 min) and plated at a density of 20,000 cells/well onto poly-D-lysine-coated 
(PDL; Sigma) 96-well plates. After 24h, cultures were exposed to 2-AG (5 μM; 
endocannabinoid and full CB1R agonist), AA (10 μM; 2-AG precursor) or to AM251 (200 
nM), an inverse CB1R agonist, alone or in combination for 4 days (pharmacology) or 7 days 
(neurite outgrowth) (10,,20). Drug treatment was performed in quadruplicates with parallel 
live imaging on an IncuCyte Zoom live-cell imaging platform (Essen Bioscience). Time-
lapse images were acquired every 2h. The growth rate of neurites in each well was 
determined as the surface area covered by neurites (soma free mode) and expressed as 
mm/mm2 surface area. Surface occupancy of neurons after 4 days in culture was expressed as 
‘body cluster area’ and expressed as percentage surface area covered by live neurons. This 
parameter was considered as a precise measure of cell survival. 
 
DNA methylation. Extracted DNA was subjected to the reduced representation bisulfite 
sequencing (RRBS) workflow as described previously (28, 29): 100 ng of DNA were 
digested at 37°C for 12h with 20 units of MspI and TaqI (New England Biolabs) in 30 μl of 
1x NEB buffer. Fill-in and A-tailing were performed by addition of Klenow Fragment 3’ > 5’ 
exo- (New England Biolabs) and dNTP mix (10 mM dATP, 1 mM dCTP, 1 mM dGTP). 
After ligation to methylated Illumina TruSeq LT v2 adaptors using Quick Ligase (New 
England Biolabs), the libraries were size selected by performing a 0.75x clean-up with 
AMPure XP beads (Beckman Coulter). The libraries were pooled in equal amounts based on 
qPCR data and bisulfite converted using the EZ DNA Methylation Direct Kit (Zymo 
Research). Bisulfite-converted libraries were enriched and quality control was performed 
using Qubit dsDNA HS (Life Technologies) and fragment length was assessed using high 
sensitivity DNA chips on a Bioanalyzer 2000 (Agilent). Sequencing was performed on an 
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Illumina HiSeq 3000/4000 instrument in single-end 50bp mode. RnBeads (30) were used for 
quality control and initial analysis of the DNA methylation data according to established 
practices (31). We summarized CpGs in 1,000 kb bins and performed differential DNA 
methylation analysis between ω-6 PUFA (n = 3) and control (n = 6) datasets using limma (32) 
(FDR-adjusted p-value < 0.05, fold change > 1.5, absolute difference > 25 percentage points). 
Locus overlap analysis (LOLA) (33) was used to calculate the relative overrepresentation of 
hypermethylated tiles with respect to three published ChIP-seq peak lists from its core 
database, corresponding to binding sites of Stat3, c-Myb, and Cebpb (34). 
 
Chromatin accessibility. Open chromatin mapping was performed with the assay for 
transposase accessible chromatin (ATAC-seq) (35) with minor adaptations (36). In each 
experiment, 1x10  cells were incubated in the transposase reaction mix (12,5 μL 2× TD 
buffer, 2 μL TN5 transposase (Illumina) 0,1% NP40 and 10,25 μL nuclease-free water) at 37 
°C for 30 min. After DNA purification with the MinElute kit (Qiagen), 1 μl of the eluted 
DNA was used in a qPCR reaction to estimate the optimum number of amplification cycles. 
Library amplification was followed by a SPRI size-selection to exclude fragments larger than 
1,200 bp. DNA concentration was measured with a Qubit fluorometer (Life Technologies). 
Sequencing was performed on an Illumina HiSeq 3000/4000 instrument in single-end 50bp 
mode. Raw sequencing data were trimmed using Skewer (37) followed by alignment to the 
GRCh38 assembly of the human reference genome with Bowtie (38) (parameters: --very-
sensitive --no-discordant). Only deduplicated, uniquely mapped reads with mapping quality 
≥30 were retained for further analysis. To identify accessible genome regions, we used 
MACS2 (39) (parameters: -q 0.1 -g hs). Following initial data processing, all subsequent 
analyses were performed in R using Bioconductor packages. After removing peaks that 
overlapped blacklisted regions from the ENCODE consortium (34) and merging all 
overlapping 2-AG peaks, we quantified for each input dataset the number of reads in the 
retained peaks. Raw read counts were loaded into DESeq2 (40) for normalization and 
differential analysis (FDR-adjusted p-value < 0.05). In our analysis, we used the sequencing 
flowcell as a covariate to account for batch effects. To further prevent disproportionate 
normalization between globally altered chromatin accessibility landscape (as observed 
between sample groups), we added random genome regions to the calculation step for the size 
factors of DESeq2 (three times as many as actual peaks). We annotated each peak with the 
closest gene (distance relative to gene start coordinate based on Ensembl v77) and used 
Enrichr for functional enrichment analysis of differentially accessible regions (41). 
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Statistics. The number of independent samples is indicated in the graphs and the number of 
animals is indicated in the figure legends. All values represent the mean ± s.d. of independent 
experiments. Samples were tested for equal variance throughout. Statistically significant 
differences were determined by either Student’s t-test (two-tailed for independent groups) or 
one-way analysis of variance (ANOVA) followed by Bonferroni’s post-hoc test (for multiple 
groups). Statistical analysis was performed with Prism 6.0 (GraphPad Software Inc.). 
Statistical significance is indicated by asterisks (*p < 0.05, **p < 0.01, ***p < 0.001 and 




Dietary ω-6 PUFA enrichment during pregnancy impacts fetal cortical architecture 
To test if fetal corticogenesis in mice undergoes life-long modifications after a prenatal diet 
enriched in ω-6 PUFAs, dams were fed a ‘fast-food-like’ hypercaloric diet with its ω-6 PUFA 
content increased through supplementation with linoleic acid and arachidonic acid (Fig. S2a) 
by ~15-fold (to ~31% of all fatty acids) while maintaining the ω-3:ω-6 ratio (Table S1), for 
either 2 weeks (‘priming protocol’; Fig. S2b) or 8 weeks (‘programming protocol’; Fig. 
S2b1) prior to conception and during pregnancy. Besides their weight gain (Fig. S2c), ω-6 
PUFA-fed dams had difficulties in conceiving (success rate of pregnancy: ~50% for both 
protocols vs. ~75% on control chow), and had fewer viable embryos (8 ± 1.08 (ω-6 PUFA) 
vs. 12 ± 1.2 (control)) but retained ~50% sex ratio. 
 
Initially, dams in the ‘programming protocol’ were pulsed with 5-ethynyl-2′-deoxyuridine 
(EdU)(22) on embryonic day (E)14.5, which coincides with the peak of cortical neurogenesis 
(42), to address if ω-6 PUFAs modify the number and positions of new-born neurons destined 
to the cerebral cortex. In E18.5 fetuses, EdU+ cells accumulated in the subventricular 
zone/deep cortical plate with a proportional decrease in neurons reaching the dorsal cortical 
plate/marginal zone that forms first in the outside-in hierarchy of cortical lamination (Fig. 1a) 
(42). These data were verified for both feeding protocols by histochemical detection of Ki67+ 
neurons (Fig. S3a), and revealed a marked increase in Ki67+ progenies at locations 
overlapping with the sites where EdU+ cells had accumulated. EdU and Ki67 do not 
differentiate between radially-migrating pyramidal cells and interneurons commuting 
tangentially (42). Therefore, we used cholecystokinin (CCK)BAC/DsRed mice whose genetically-
tagged DsRed+ progeny are predominantly GABA interneurons (co-expressing Gad1, Fig. 
S3b-b2) and populate the cerebral marginal zone (18). Both maternal feeding regimes led to a 
significant redistribution of DsRed+ neurons with their loss in the marginal zone 
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(interneurons) and accumulation in deep cortical layers (likely pyramidal cells; Fig. 1b and 
S3d,d1), establishing impaired cortical lamination upon maternal ω-6 PUFA enrichment. 
Next, axon-specific morphometry (18, 19) using neural cell adhesion molecule L1 
(L1NCAM; Fig. S3c) revealed that corticofugal axons coalesced into enlarged fascicles that 
spread in the callosal primordium (‘programming protocol’; Fig. 1c,c1) in E18.5 fetuses 
whose mothers were on the ω-6 PUFA-enriched diet. This contrasted with control cases, 
which had corticofugal axons spaced evenly as fine-caliber fascicles (19, 43). These data 
suggest that maternal dietary choices during pregnancy carries a risk for fetal cortical 
abnormalities. 
 
The misplacement of cortical neurons and their axonal defects observed upon hyperchaloric 
feeding regimes show striking similarities with failures of cortical wiring upon genetic (19, 
43) and pharmacological (43) disruption of endocannabinoid signaling in the developing 
nervous system. This notion is particularly relevant since CCK+ interneurons in the fetal 
cerebrum preferentially express CB1Rs (9) and use endocannabinoids as focal cues for 
chemotaxis (Fig. S1a,b). Both linoleic acid and AA, available in excess in the hypercaloric 
diet (Table S1), can act as endocannabinoid precursors (Fig. S2a). This is compatible with 
altered AEA and 2-AG levels in fetal cerebrum (shown from the ‘programming protocol’; 
Fig. 1d) with a shift favoring the availability of 2-AG, a full agonist at CB1Rs, which we 
interpreted as a consequence of increased precursor bioavailability and processing. 
Desensitization of CB1Rs together with the expressional deregulation of both the CB1R and 
monoacylglycerol lipase (MAGL), the enzyme degrading the bulk of 2-AG in fetal brain (6, 
43), is an effective means to impart a ‘loss-of-function’ signature on cortical architecture 
(19). Indeed, both CB1Rs (Fig. 1e and S4a) and MAGL (Fig. S4b) showed >50% loss at the 
protein level with their mRNA transcripts unaffected (Fig. S4c,d), in fetuses from 
hyperchaloric diet-exposed dams, regardless of the length of the feeding protocol. 
Cumulatively, these data suggest that excess ω-6 PUFA intake increases endocannabinoid 
precursor availability and signaling to produce CB1R inactivation over time, phenocopying 
mice with genetic Cnr1 loss of function (19). The biological significance of AA-to-
endocannabinoid conversion as a metabolic principle is reinforced by the AM251 sensitivity 
of neurite growth retardation upon AA supplementation (10  μM, Fig. S1a,b). 
 
 
Dietary ω-6 PUFA enrichment reduces IgCAM expression in fetal cerebrum 
We used isobaric tagging for relative and absolute quantitation (iTRAQ) (19) as a means to 
search for molecular determinants underpinning neuronal deficits. In E18.5 cerebri (including 
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cortical plate and dorsal hippocampus) (Fig. 2a), increased maternal intake of ω-6 PUFAs 
(‘programming protocol’) significantly altered the abundance of 208 proteins, which were 
assigned to 12 major functional clusters by gene ontology (Fig. 2a1). Twelve proteins (6%) 
belonged to the cluster of ‘cell adhesion/extracellular matrix composition’ (Fig. 2a1). A 
refined analysis focusing on male embryos returned 215 proteins as significantly different, 
including 8 ‘cell adhesion molecules’ (4%) as topmost male-specific targets: members of the 
immunoglobulin family of cell adhesion molecules (IgCAMs) (44) were coincidently and 
significantly down-regulated along with presynapse-specific synaptosomal-associated protein 
25 (Fig. 2a2), vesicle-associated membrane protein 2 and syntaxins (Table S2), indispensable 
for presynaptic neurotransmitter release at mature synapses. 
 
Next, we focused on limbic system-associated membrane protein (Lsamp) because of its 
confinement to cortical structures in the dorsal telencephalon(45) (Fig. S5a) and interaction 
with other IgCAMs to regulate neurite outgrowth(46) (Fig. S5b). By combining qPCR (Fig. 
2b) and Western blot analyses on subcellular fractions (Fig. 2c), we verified that heightened 
ω-6 PUFA intake, even for short periods, disrupted Lsamp mRNA and protein expression and 
subcellular localization. Notably, and even if its distribution is more general in the fetal 
hippocampus (Fig. 2d-d4), Lsamp was invariably but not exclusively found around 
CCKBAC/DsRed+ fetal interneurons (Fig. 2d1-d4 and S5c,d) by E18.5, thus anatomically linking 
IgCAM deregulation to the differentiation and placement of CB1R+ cell populations (19, 43). 
We have genetically linked Lsamp expression to upstream CB1R activity by demonstrating 
significantly reduced Lsamp mRNA expression in both Cnr1-/- fetuses (E18.5; Fig. 2e) and 
when exposing primary cortical neurons to AM251 (200 nM), a selective CB1R antagonist 
(Fig. 2f). We could similarly implicate L1CAM, NCAM and neurotrimin, alternative 
members of the IgCAM family, in cortical deficits upon maternal ω-6 PUFA overfeeding 
because of their mRNA expression being significantly reduced by both ‘priming’ and 
‘programming’ protocols (Fig. 2g) and upon CB1R ablation (Cnr1-/-; Fig. 2h). Overall, these 
data suggest that IgCAMs are molecular targets of CB1R-mediated signal transduction 
cascades. Moreover, they qualify the transcriptional modification of IgCAMs as a candidate 
mechanism (Fig. 3a) through which maternal ω-6 PUFA preference impairs fetal brain 
development in male embryos, a hypothesis compatible with a role for endocannabinoids in 





ω-6 PUFA enrichment reduces chromatin accessibility of transcription factors 
downstream from CB1Rs 
The design logic of CB1R activity posits the recruitment of elaborate transcription factor 
networks with signal transducer and activator of transcription 3 (STAT3) being a prototypic 
effector to regulate CB1R-dependent neurite outgrowth (47). Here, we reasoned that 
coincident expressional hindrances within the IgCAM family might indicate consensus 
transcription factor (TF) inactivation. By using publicly available gene expression microarray 
dat a(47) to select TF targets, we show that both ‘priming’ (Fig. 3b) and ‘programming’ 
protocols (Fig. S6a) significantly reduced the expression of Stat3, myeloblastosis oncogene 
(Myb) and CCAAT/enhancer-binding protein  β (Cebpb) in fetal cortices (E18.5). 
 
Next, we argued that long-lasting TF repression might be brought about by epigenetic 
modifications particularly since phytocannabinoids that engage CB1Rs disrupt brain 
development by histone modifications (48). DNA methylation is a powerful means of gene 
regulation (49), which leaves the longest-lasting marks on chromatin. First, we performed 
genome-wide DNA methylation profiling in E18.5 fetal male brains after the ‘priming’ 
protocol and found broad gene repression along with CpG islands being hypermethylated. 
Second, enrichment analysis based on ChIP-seq data sets using the LOLA algorithm of 
genome-wide differences in DNA methylation revealed significant enrichments for the TFs 
STAT3, MYB and CEBPB in hypermethylated regions (Fig. 3c). Third, we used the assay of 
transposase-accessible chromatin (ATAC-seq), which is suitable to differentiate between 
effectively open (potentially active) and closed (potentially repressed) chromatin regions 
whilst also identifying the TFs that bind promoter regions of differential accessibility (50). To 
mechanistically link CB1R activity and changes in the landscape of chromatin accessibility 
without confounds that could influence read-outs in protracted in vivo experiments, we 
performed ATAC-seq after treating primary cultures with 2-AG (5 µM) or AM251 (200 nM) 
for 7 days (Fig. 3d). Here, 2-AG reduced both Lsamp and Stat3 mRNA expression, 
recapitulating our in vivo results (Fig. 3e; for AM251 see Fig. S6b). 1,423 genomic regions 
were identified with differential accessibility upon treatment, with decreased accessibility 
after both AM251 (Fig. S6c) and 2-AG exposures but with 2-AG showing higher effect 
amplitudes (Fig. 3f). This was particularly notable for the accessibility of the Stat3 promoter 
(Fig. 3g,g1 and S6d,d1). These observations were interpreted as 2-AG-induced receptor 
activation followed by permanent desensitization over 7 days (51). We then sought to gain 
broader insights in the biological relevance of signature regions with sensitivity to CB1R-
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mediated signaling by performing gene set enrichment analysis of all genes associated with 
differentially-accessible genomic loci using Enrichr (52). Based on ChIP-seq data available 
from the ENCODE project, an unexpectedly high fraction of the genomic loci losing 
accessibility upon 2-AG treatment occurred in the proximity of genes that are targets of TFs 
including BRCA1, FOS, CREB1 (Fig. 3h and S6e) that drive CB1R-induced neurite 
outgrowth (43, 47). As such, their inactivation provides a transcriptional platform for 
endocannabinoid-induced axonal growth retardation upon CB1R desensitization (Fig. 3i and 
S6f) (19, 43). Thus, our results outline an epigenetic regulatory framework to limit the 




Life-long effects of maternal ω-6 PUFA preference in first generation offspring 
Epigenetic reprogramming of TF networks is biologically advantageous as a means to 
enforce genomic changes for as long as the lifetime of an organism (49). In accordance with 
this principle, we have assessed if key parameters of cortical reorganization endure into the 
adulthood of ω-6 PUFA-exposed offspring after programming feeding protocol. Firstly, AEA 
and 2-AG contents remained reflective of those in fetal brain, with significantly increased 2-
AG levels detected on postnatal day 75 (Fig. 4a). At the same time, ω-6 PUFA-exposed 
offspring showed significantly reduced cortical CB1R load (Fig. 4b), which we attribute to 
the presence of and adaptation to persistent 2-AG excess. Secondly, subcellular distribution 
of LSAMP, particularly its membrane-bound fraction, remained reduced (Fig. 4c), suggesting 
disrupted cell adhesion. Thirdly, genetic ablation of Lsamp provokes heightened behavioral 
responses to novel stressors in mice (53) and Lsamp gene polymorphisms correlate with 
depressive traits in humans (54). Therefore, we determined anxiety-like behaviors in the 
elevated plus-maze and open-field paradigms. Both tests revealed significant anxiety, 
reflected by shortened exploration of open surfaces (center of arena [Fig. 4d] and open arm 
entries [Fig. 4e]). Cumulatively, these data suggest that deregulated endocannabinoid 
signaling could contribute to the life-long manifestation of depression-like behaviors in mice 
born to dams consuming ω-6 PUFA-enriched chow during pregnancy. In agreement with our 
hypothesis that pre-conception and congenital excess of dietary ω-6 PUFAs and ensuing 
elevation of brain 2-AG levels cause the anxiety phenotype observed here, Mgll-/- mice (51), 
which lose the ability to hydrolyze endocannabinoids, exhibit chronic CB1R desensitization 
and present anxiety-like behaviors. In contrast, life-long n-3-fatty acid deprivation impairs 






In the present report we show transgenerational consequences of increasing the ω-6 PUFA 
nutritional content during pregnancy in mice on the development of the offsprings' nervous 
system. We outline that a critical mechanism involved is the engagement of the 
endocannabinoid system. As such, nutritional ω-6 PUFA-derived endocannabinoids 
desensitize CB1Rs thereby altering neurogenesis, neuroblast commitment to the cerebral 
cortex and the formation of axonal connectivity. We suggest a link between long-lasting 
changes of cortical architecture and epigenetic repression of regulatory TF networks 
downstream from CB1Rs that control neuronal differentiation (43, 47). The finding that many 
of the TF networks associated with axonal growth are epigenetically controlled by 
endocannabinoids might be relevant to public health in view of the ever-increasing world-
wide pandemic of excess ‘Western’ diet and ensuing metabolic and behavioral dysfunctions 
(14). 
 
A series of human longitudinal studies (and experimental reports) (12, 15) pinpoint optimal 
fatty acid composition in maternal diet during pregnancy as a means to reduce the risk of 
childhood diabetes, hypertension and obesity. Despite significant efforts in raising public 
awareness on the benefits of ω-3 PUFA-enriched diets (‘fish’ or ‘Japanese’ diets) for 
transgenerational disease prevention, the prevalence of dietary routines favoring ω-6 PUFAs 
is raising given easy access to high-fat fast food with extraordinary caloric composition. A 
reason for this is that intake of a concentrated source of dietary energy is considered 
rewarding particularly if it coincides with the intake of excess sugar or salt to raise flavor and 
aroma (56). Accordingly, preschool children born to mothers who preferred ω-3 PUFA-rich 
nutrients during pregnancy show higher cognitive scores (57) and are less prone to neurologic 
birth defects (58). In contrast, extreme pre-pregnancy weight is linked as a critical risk factor 
to attention deficit hyperactivity disorder (ADHD) (59), schizophrenia (60) and anxiety (61). 
Notably, the endocannabinoid system is a critical molecular component of the 
neuropathology of these neuropsychiatric disorders in both children and adults (62, 63) with 
an association between lowered CB1R, CCK and GAD67 expression in cortical interneurons 
established as a key variable (64, 65). Our data are compatible with these considerations in 
humans, and provide a critical and causal link, at least in rodent models, between ω-6 PUFA-
enriched diets during pregnancy and lactation, permanent neurochemical modifications that 
endure into adulthood and anxiety-like behaviors. Our in vitro finding that AA-to-
endocannabinoid conversion is a cell-intrinsic metabolic feature is significant to emphasize 
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that not only systemic increases in circulating endocannabinoid levels but also excess 
endocannabinoid production in situ in developing organs could contribute to and diversify 
undesired ω-6 PUFA effects. Nevertheless, since AA is a precursor of a plethora of 
alternative bioactive products, many being essential for cell survival and function, we 
emphasize that balancing ω-3:ω-6 PUFA intake might be ultimately beneficial for neuronal 
development. 
 
Even though our study focused on changes in the fetal nervous system, one ought to consider 
the constant interplay between the brain and peripheral organs through, e.g., long-range 
hormonal mechanisms. This notion is particularly relevant when studying the 
endocannabinoid system with its critical roles in the formation of e.g., bone (66), muscle 
(67), fat depots (68), immune system and pancreas (69) through recruitment of vastly 
different ligands and receptor systems. In obesity, CB1R expression increases in multiple 
tissues (70) along with elevated circulating 2-AG levels as shown in both obese individuals 
(71) and in insulin-resistant obese postmenopausal women (72). Despite these inferences, we 
are acutely aware that the translational value of experimental data from laboratory rodents is 
often limited to human diseases. One confound we highlight is the C57Bl6/J strain used here, 
which is a favored laboratory subject due to its propensity to develop metabolic syndrome on 
high-fat diets (16, 68, 73). Nevertheless, the fact that both 2-AG and AEA concentrations are 
increased in the brain (16) and peripheral tissues (74) in conjunction with desensitization of 
brain CB1Rs (16) in mice upon diet-induced obesity justify our choice of the animal model. 
Another concern is the timing and length of ω-6 PUFA administration because our 
experimental protocols precluded the pinpointing of a specific developmental window with 
peak sensitivity of the nervous system to imbalanced nutrient supply. A driving force behind 
our experimental design was that dietary preferences in humans are of long-lasting nature, 
often spanning years and decades. As such, the reduced probability of conception in obese 
females here is reminiscent of population data in humans (75), and lasts throughout 
pregnancy. Moreover, the metabolic multi-enzyme processing of ω-6 fatty acids is precisely 
controlled with brief exposures being well-tolerated and compensated. Therefore, an 
experimental design predisposing to heightened ω-6 PUFA levels in the long term is 
amenable for discovery research at the cellular and molecular levels. 
 
In summary, we show that maternal dietary choices before and during pregnancy define brain 
development of the fetus, alike shown earlier for neonates and adolescents (13), and strongly 
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Legends to Figures 
Fig. 1. ω-6 PUFA-enriched diets modulate cell migration by disengaging the 
endocannabinoid system. a,b, Representative images (left) and quantification (right) of 
EdU+ (a; ‘programming protocol’) and CCKBAC/DsRed+ (b; ‘priming protocol’) neurons in 
cortical layers of male embryos at E18.5. Cell counts were performed on equal cortical tissue 
surfaces in equal binned players (numbered consecutively from 1 to 10), and expressed as 
absolute numbers. Figure S3 is referred to for direct comparisons of the two maternal feeding 
protocols with regards to their impact on cortical reorganization in the offspring. Scale bars = 
20  μm. Abbreviations: cp, cortical plate; mz, marginal zone; svz, subventricular zone. c,c1, 
Immunofluorescence histochemistry and quantification of the transverse diameter (c1) of 
first-order axonal fascicles in male E18.5 embryos, labeled for L1NCAM, in the cortical 
intermediate zone after nutrient-induced reprogramming. d, Anandamide (AEA) and 2-AG 
levels in E18.5 cerebral tissue of mice (both sexes) after the ‘programming’ protocol. e, 
Western analysis of CB1R protein levels in E18.5 cerebral tissue of mixed sexes after both 
maternal priming (Pri) and programming (Pro) feeding protocols. Total protein load was 
visualized by Cy5 dye reagent and used to normalize CB1R expression at 53 kDa (arrow). 
Quantitative data are shown to the right. (*p < 0.05, **p < 0.01, n = 5 mice/group. Data are 
means ± s.d. from three independent experiments. 
 
 
Fig. 2. Dietary ω-6 PUFA enrichment reduces IgCAM expression in fetal cerebrum. a-
a2, Origin of cortical tissue (n = 4 biological replicates/group) used for quantitative iTRAQ 
proteomics (a), ontology classification of significantly altered proteins in mixed sex embryos 
through primary function assignment (a1) and topmost modified protein targets (ω-6 PUFA-
enriched diet vs. control) obtained after the ‘programming’ protocol in male embryos (a2). b, 
Lsamp mRNA expression after either the ‘priming’ (Pri) or the ‘programming’ (Pro) protocol 
in fetal cortices on E18.5. mRNAs were quantified by qPCR and normalized to Gapdh as a 
housekeeping standard. Data were expressed relative to fetuses from pregnancies on control 
chow. c, Western analysis of LSAMP in subcellular fractions (cytosol [cyto]; membrane 
fraction [MF]) of fetal cerebral tissues after ‘programming’ protocol. d-d4, Representative 
image of LSAMP immunoreactivity (d1), particularly in the proximity of CCK+ interneurons 
(d2), in E18.5 hippocampi of CCKBAC/DsRed mice. e,f, Lsamp mRNA in Cnr1-/- cortices (e) and 
in E18.5 cortical neurons treated with AM251 for 96h (f). g,h, IgCAM mRNA levels after 
both ‘priming’ and ‘programming’ protocols (g) and in Cnr1-/- cortical tissue on E18.5 (h). 
mRNA expression was normalized to Gapdh. Lsamp expression was normalized to control-
fed (c,g) or wild-type (e,h) mice. All data are on male mice. Abbreviations: CA1, cornu 
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Ammonis subfield 1; cng, cingulate cortex; Cpu, caudate putamen; DG dentate gyrus; f, 
fimbria; Ht, hypothalamus; Ntm, neurotrimin; sctx, somatosensory cortex; Th, thalamus. 
Scale bars = 75 μm (d), 8 μm (d, inset). *p < 0.05, **p < 0.01, n = 3 mice/group. Data are 
means ± s.d. from triplicate experiments.  
 
 
Fig. 3. ω-6 PUFA-enriched diets reduce chromatin accessibility of transcription factors 
regulated by CB1R activation. a, Schematic representation of signaling events and 
interactions. Grey color indicates the site of action for AM251 used for pharmacological 
probing. b, Stat3, c-Myb and Cebpb transcription factor mRNA levels in E18.5 cortical tissue 
(‘priming protocol’). mRNAs were quantified by qPCR and normalized to Gapdh. 
Expression was normalized to control mice. *p < 0.05, n = 3 mice/group. c, Bar graph 
showing the relative enrichment of overlaps of transcription factor binding sites and genomic 
regions (1kb tiles) with increased DNA methylation in E18.5 cortical tissue upon excess ω-6 
PUFA exposure (‘priming protocol’). LOLA was used to test the enrichment of the three 
selected transcription factors using published ChIP-seq peaks from ENCODE and CODEX. 
*p < 0.05, **p < 0.01, n = 3 mice/group. d, Timeline of in vitro CB1R agonist (2-AG, 5  μM) 
and antagonist (AM251, 200 nM see also SI Fig. 6) exposure. DIV = day in vitro. *p < 0.05, 
Data were expressed as means ± s.d. from three independent experiments. e, Lsamp and Stat3 
mRNAs in E18.5 primary cortical neurons after 2-AG (5  μM) exposure. mRNA expression 
(relative to Gapdh) was normalized to control. f, Heatmap of ATAC-seq data showing 
decreased chromatin accessibility after 2-AG treatment. Numbers denote the normalized and 
scaled read count per ATAC-seq peak. R1-R6 for both control and 2-AG treatments identify 
biological replicates from two independent experiments. g-g1, Genome browser plot showing 
ATAC-seq signal intensity across cortical neurons in the vicinity of the Stat3 gene after 2-AG 
application, and relative quantification (g1). DeSeq2-normalized read counts. h, Enrichment 
analysis for all differentially accessible regions determined using Enrichr. ****p < 0.0001. i, 
Dynamic time-course analysis of neurite outgrowth after 2-AG exposure for 7 days aided by 
an IncuCyte automated imaging system. **p < 0.01, ****p < 0.0001. Data represent 
means ± s.d. from three independent experiments. All in vivo and in vitro data are on male 
mice. An equivalent dataset on tissues from the ‘programming protocol’ at E18.5 is shown in 
SI Fig. 6. 
 
 
Fig. 4. Life-long effects of maternal ω-6 PUFA preference in first generation offspring. 
a, Anandamide (AEA) and 2-AG levels in cortical tissues of mixed sexes on postnatal day 
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(PND) 75 after exposure to the ‘programming’ protocol. **p < 0.01, n = 3-4 mice/group. b,c, 
Western analysis of CB1R (b) and LSAMP (c) protein load in cerebral tissue of mixed sexes. 
CB1R was enriched in membrane fractions, while LSAMP was detected in both the cytosol 
(cyto) and membranes (mf). Quantitative data are from triplicate experiments. d, Open-field 
behaviors of male mice born to and weaned from the ‘programming protocol’, including the 
total distance travelled (m), the time spent (s) in the center of the arena and the velocity of 
movement (cm/s). *p < 0.05, n = 4 mice/group. e, Elevated plus-maze behaviors of male 
offspring, such as the distance travelled (cm) on, the time spent (s) in and the number of 
entries (n) into open arms. *p < 0.05, **p < 0.01, n = 4 mice/group. 




